These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17029152)

  • 1. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
    Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
    Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
    [No Abstract]   [Full Text] [Related]  

  • 2. [Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia].
    Nielsen JL
    Ugeskr Laeger; 2003 May; 165(20):2111. PubMed ID: 12812107
    [No Abstract]   [Full Text] [Related]  

  • 3. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 4. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
    Uchiyama M; Ikeda T
    Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib in chronic myeloid leukemia.
    Krause SW; Holler E
    N Engl J Med; 2007 Apr; 356(17):1780; author reply 1780. PubMed ID: 17460235
    [No Abstract]   [Full Text] [Related]  

  • 8. [Imatinib--en epoch-making new drug against chronic myeloid leukemia].
    Lakartidningen; 2003 Jun; 100(26-27):2283. PubMed ID: 12872372
    [No Abstract]   [Full Text] [Related]  

  • 9. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imatinib. An anticancer agents indicated in the treatment of chronic myeloid leukemia]].
    Taéron C
    Rev Infirm; 2004 Feb; (98):39-40. PubMed ID: 15042992
    [No Abstract]   [Full Text] [Related]  

  • 11. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
    Tunca Y; Güran S
    Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
    Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
    Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
    [No Abstract]   [Full Text] [Related]  

  • 13. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
    Champlin RE; Kantarjian H
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
    [No Abstract]   [Full Text] [Related]  

  • 14. Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
    Anthony N; Shanks J; Terebelo H
    Leuk Res; 2010 Sep; 34(9):1250-1. PubMed ID: 20646761
    [No Abstract]   [Full Text] [Related]  

  • 15. An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy.
    Maeda T; Mutoh T; Muta H; Nakayama M; Nakajima Y; Ikuta T; Yasuda M; Etoh T; Shimizu K; Nakazaki Y; Hiroyama T; Somada S; Kurita R; Tani K; Shiratsuchi M; Nishimura J
    J Am Geriatr Soc; 2004 Oct; 52(10):1783-4. PubMed ID: 15450069
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
    Jin J; Chen H; Cao L
    Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of chronic myeloid leukemia with imatinib].
    Ohnishi K
    Gan To Kagaku Ryoho; 2011 May; 38(5):746-8. PubMed ID: 21702117
    [No Abstract]   [Full Text] [Related]  

  • 18. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
    Mariani S; Tornaghi L; Sassone M; Basciani S; Buzzetti R; Gambacorti-Passerini C; Spera G; Gnessi L
    Leuk Res; 2010 Jan; 34(1):e5-7. PubMed ID: 19717189
    [No Abstract]   [Full Text] [Related]  

  • 20. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M; Alimena G
    Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.